Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology

E Schrezenmeier, T Dörner - Nature Reviews Rheumatology, 2020 - nature.com
Despite widespread clinical use of antimalarial drugs such as hydroxychloroquine and
chloroquine in the treatment of rheumatoid arthritis (RA), systemic lupus erythematosus …

Novel paradigms in systemic lupus erythematosus

T Dörner, R Furie - The Lancet, 2019 - thelancet.com
The heterogeneity of systemic lupus erythematosus (SLE), long recognised by clinicians, is
now challenging the entire lupus community, from geneticists to clinical investigators …

Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge

A Dima, C Jurcut, F Chasset… - Therapeutic …, 2022 - journals.sagepub.com
The antimalarial hydroxychloroquine (HCQ) has demonstrated several crucial properties for
the treatment of systemic lupus erythematosus (SLE). Herein, we reviewed the main HCQ …

An update on the management of childhood-onset systemic lupus erythematosus

VC Trindade, M Carneiro-Sampaio, E Bonfa, CA Silva - Pediatric Drugs, 2021 - Springer
Childhood-onset systemic lupus erythematosus (cSLE) is a prototype of a multisystemic,
inflammatory, heterogeneous autoimmune condition. This disease is characterized by …

10 Years of belimumab experience: What have we learnt?

RA Levy, T Gonzalez-Rivera, M Khamashta, NL Fox… - Lupus, 2021 - journals.sagepub.com
Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease
affecting both adults and children. Belimumab is the only biologic approved for SLE, and the …

Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues

S Porta, A Danza, M Arias Saavedra… - Journal of clinical …, 2020 - mdpi.com
Since the discovery of glucocorticoids (GCs), their important anti-inflammatory effect, rapid
mechanism of action, low cost, and accessibility have made them one of the mainstays of …

Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International …

MF Ugarte-Gil, J Hanly, M Urowitz, C Gordon… - Annals of the …, 2022 - ard.bmj.com
Objective To determine the independent impact of different definitions of remission and low
disease activity (LDA) on damage accrual. Methods Patients with≥ 2 annual assessments …

Systemic lupus erythematosus: state of the art on clinical practice guidelines

F Tamirou, L Arnaud, R Talarico, CA Scirè… - RMD open, 2019 - rmdopen.bmj.com
Systemic lupus erythematosus (SLE) is the paradigm of systemic autoimmune diseases
characterised by a wide spectrum of clinical manifestations with an unpredictable relapsing …

Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort

VR Pimentel-Quiroz, MF Ugarte-Gil, GB Harvey… - Lupus, 2019 - journals.sagepub.com
Aim The aim of this study was to identify factors predictive of serious infections over time in
patients with systemic lupus erythematosus (SLE). Methods A multi-ethnic, multi-national …

Системная красная волчанка: новые горизонты диагностики и терапии

СК Соловьев, ЕА Асеева, ТВ Попкова… - Научно …, 2020 - cyberleninka.ru
Системная красная волчанка (СКВ)-системное аутоиммунное ревматическое
заболевание неизвестной этиологии, характеризующееся гиперпродукцией …